Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Exposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria

dc.contributor.authorSevillano Fernández, David
dc.contributor.authorAguilar, Lorenzo
dc.contributor.authorAlou Cervera, Luis
dc.contributor.authorGiménez, María José
dc.contributor.authorGonzález Hidalgo, Natalia
dc.contributor.authorTorrico, Martha
dc.contributor.authorCafini. Fabio
dc.contributor.authorGarcia-Rey, César
dc.contributor.authorGarcia-Escribano, Natalia
dc.contributor.authorPrieto Prieto, José
dc.date.accessioned2024-07-24T08:01:42Z
dc.date.available2024-07-24T08:01:42Z
dc.date.issued2010-08
dc.description.abstractThis study explored tigecycline exposure-bacterial responses in pharmacodynamic simulations (in vitro kinetic model) using different inocula. One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum beta-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25 microg/mL) were used. A computerised pharmacodynamic bicompartmental model simulated three tigecycline twice-daily dosing regimens over 48h: 50mg (100mg loading dose); 100mg; and 150 mg. Areas under bacterial growth curves were calculated, and differences between the growth curve used as control and the killing curve of bacteria exposed to tigecycline (ABBC) were determined. With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens. ABBCs obtained with the 100mg regimen using standard inocula were similar to those obtained with the 150 mg regimen when using high inocula (ca. 1 x 10(7)CFU/mL). Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75 log CFU x h/mL with standard inocula and 63.33 log CFU x h/mL with high inocula). An increase in tigecycline dosing appears to be an interesting therapeutic option to maximise antibacterial activity owing to its linear pharmacokinetics and pharmacodynamics, especially when severe infections with high bacterial load are suspected.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipWyeth Farma S.A.
dc.description.statuspub
dc.identifier.citationSevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, Cafini F, Garcia-Rey C, Garcia-Escribano N, Prieto J. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Int J Antimicrob Agents. 2010 Aug;36(2):137-44
dc.identifier.doi10.1016/j.ijantimicag.2010.03.021
dc.identifier.issn0924-8579
dc.identifier.officialurlhttps://doi.org/10.1016/j.ijantimicag.2010.03.021
dc.identifier.relatedurlhttps://www.sciencedirect.com/science/article/pii/S0924857910001548
dc.identifier.urihttps://hdl.handle.net/20.500.14352/107080
dc.issue.number2
dc.journal.titleInternational Journal of Antimicrobial Agents
dc.language.isoeng
dc.page.final144
dc.page.initial137
dc.publisherElsevier
dc.rights.accessRightsrestricted access
dc.subject.cdu611.02
dc.subject.keywordStaphylococcus aureus
dc.subject.keywordEnterococcus faecium
dc.subject.keywordGlycylcyclines
dc.subject.keywordPharmacodynamics
dc.subject.keywordInoculum effect
dc.subject.ucmMicrobiología médica
dc.subject.unesco2414 Microbiología
dc.titleExposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number36
dspace.entity.typePublication
relation.isAuthorOfPublication518c916a-df78-48cc-9bf7-6a2aaca7d6a2
relation.isAuthorOfPublication889e4dc3-c630-429e-be0f-7f0df2cff492
relation.isAuthorOfPublication41cae2d7-0146-4705-b653-a302a81db4d0
relation.isAuthorOfPublication84cd82de-c5ea-4fed-a347-4ed15fb3bcc8
relation.isAuthorOfPublication.latestForDiscovery518c916a-df78-48cc-9bf7-6a2aaca7d6a2

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2010 IJAA Sevillano.pdf
Size:
624.69 KB
Format:
Adobe Portable Document Format

Collections